Clinical Trials Directory

Trials / Completed

CompletedNCT01267227

Effect of Pterostilbene on Cholesterol, Blood Pressure and Oxidative Stress

Status
Completed
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
80 (actual)
Sponsor
University of Mississippi Medical Center · Academic / Other
Sex
All
Age
18 Years – 88 Years
Healthy volunteers
Not accepted

Summary

Pterostilbene is one of several stilbenes found in certain berries, particularly blueberries, that have demonstrated pre-clinical benefit to cholesterol, blood pressure, and oxidative stress. The purpose of this study is to evaluate whether pterostilbene will help control cholesterol and blood pressure, as well as improve markers for oxidative stress in patients with dyslipidemia meeting inclusion criteria. The investigators also want to look at the safety of pterostilbene in these patients.

Detailed description

Subjects will be divided into one of four groups: (1) pterostilbene 50 mg twice daily; (2) pterostilbene 125 mg twice daily; (3) pterostilbene 50 mg/grape extract 100 mg twice daily; (4) matching placebo twice daily taken either one hour before or two hours after a meal. Blood and urine will be collected at enrollment and final study visits. If the patient's low density lipoprotein-C (LDL-C) or total cholesterol (TC) is not within the inclusion criteria based on enrollment blood drawn, the patient will not be allowed to initiate study medication. All study visits will consist of brief clinical examination (including vital signs), subjective adverse event reporting, and fasting donated blood and urine for clinical laboratory tests. Pill counts will be done to assess compliance.

Conditions

Interventions

TypeNameDescription
DRUGPterostilbene 50 mg twice dailyPterostilbene 50 mg twice by mouth daily for 6 to 8 weeks
DRUGPlaceboMatching placebo by mouth twice daily for 6 to 8 weeks
DRUGGrape ExtractGrape extract 100 mg twice daily for 6-8 weeks
DRUGPterostilbene 125 mg twice dailyPterostilbene 125 mg twice daily for 6-8 weeks

Timeline

Start date
2010-12-01
Primary completion
2012-02-01
Completion
2012-02-01
First posted
2010-12-28
Last updated
2018-01-10
Results posted
2013-05-03

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01267227. Inclusion in this directory is not an endorsement.